IDT buys VH Bio's oligo business

29 March 2009

Integrated DNA Technologies, a leading US oligonucleotide synthesis firm, has purchased the oligo business of VH Bio, based in Gateshead,  the UK. IDT will supply VH Bio's customers from its own state-of-the-art  facility in Leuven, Belgium, while building on the local customer  service for which VH Bio has been renowned in the UK. Financial terms  have not been disclosed.

As a result, current VH Bio oligo customers will have access to a much  broader range of products, with 100% quality control-checked sequences  and next-day delivery. VH Bio will continue to distribute its full  range of other products for immunologists/molecular biologists.

IDT and VH Bio have also announced an agreement to work together to grow  IDT's oligonucleotide business in the UK. The two companies will combine  efforts to introduce the US group's market-leading products to  scientists throughout the country.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight